scholarly journals Metabolic tandem: non-alcoholic fatty liver disease and pancreatic steatosis; therapeutic significance of probiotics (clinical case)

2020 ◽  
Vol 48 (3) ◽  
pp. 70-75
Author(s):  
O. O. Bondarenko ◽  
M. I. Sorochka
Keyword(s):  
Metabolic Syndrome ◽  
Liver Disease ◽  
Gut Microbiota ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Clinical Case ◽  
Alcoholic Fatty Liver ◽  
Pancreatic Steatosis ◽  
Alcoholic Fatty Liver Disease

Non-communicable diseases are a serious global problem for humanity. Metabolic syndrome, cardiovascular disease, type 2 diabetes, obesity, and their complications lead to increased mortality and reduce quality of patients’ life. Non-alcoholic fatty liver disease (NAFLD) is currently recognized as one of the most common causes of chronic liver disease worldwide. Current scientific evidence suggests that there is a close relationship between the gut microbiota and chronic pathologies. The results of studies have established the existence of cause and effect relations between impaired microbiocenosis of the intestine, imbalance of the immune system, as well as in one of the key pathogenetic roles in the development and progression of NAFLD, pancreatic steatosis, increasing intestinal permeability, reducing the protective properties of mucosa, enhancing translocation of microorganisms into the systemic circulation. As no conventional approaches to the diagnosis and treatment of patients with NAFLD and metabolic syndrome have been developed at present, the therapy of such patients should be directed, first of all, to factors that contribute to their development and progression. Considering the latest research findings, the role of gut microbiota in the pathogenesis of metabolic syndrome is justified. The use of techniques affecting this correlation is substantiated. A promising method of treating such diseases is the prescription of pre- and probiotics to modify the gut microbiota. This article analyzes the case of a patient with NAFLD, pancreatic steatosis, who used a therapy that had an effect on the patient’s microbiota. The article contains system analysis, bibliosemantics, and case analysis of a specific patient. The sources were obtained from the scientific and statistical database of medical information. This clinical case highlights the relevance of this problem in medical practice and the feasibility of further research in this field. The impact of microbiome on human body is significant, and correcting disorders can reduce the risk of associated diseases. Therefore, preventing and correcting early-stage pathologies will reduce mortality rate and improve patients’ quality of life.

scholarly journals Non-alcoholic fatty liver disease in a young patient with obesity, hyperandrogenism, postcholecystectomy syndrome and reactive pancreatitis. A clinical case

2020 ◽  
Vol 47 (2) ◽  
pp. 50-53
Author(s):  
O. O. Bondarenko ◽  
M. I. Sorochka
Keyword(s):  
Metabolic Syndrome ◽  
Liver Disease ◽  
Fatty Liver ◽  
Young Patient ◽  
Fatty Liver Disease ◽  
Clinical Case ◽  
Alcoholic Fatty Liver ◽  
Postcholecystectomy Syndrome ◽  
The Metabolic Syndrome ◽  
Alcoholic Fatty Liver Disease

Non-alcoholic fatty liver disease (NAFLD) is a problem that is getting increasingly important and is often considered in the literature as a sign of liver damage in the metabolic syndrome. Currently, there is a tendency to rapid growth and rejuvenation of patients with this pathology. Metabolic syndrome, which is a polyetiological disease and is characterized by metabolic disorders and the launch of various pathological cascade reactions, can cause cardiovascular diseases, diabetes mellitus and their complications. Problem of comorbidity leads to deterioration in the quality of life of the patient and in severe cases can cause death. The article describes a clinical case of newly diagnosed NAFLD in a young patient with obesity in comorbidity with hyperandrogenism, postcholecystectomy syndrome, and reactive pancreatitis. The article presents a system analysis, bibliosemantics and case analysis of a particular patient with NAFLD. The search for sources was carried out using the scientific and statistical database of medical information. The absence of pathognomonic signs and complaints of this disease draws the attention of scientists and clinicians to conduct a comprehensive study of this problem, as well as improving the detection system of NAFLD in the early stages. This will help to avoid the development of the disease and various complications associated with the metabolic syndrome, as well as save and improve the patient’s life. Fighting against the “diseases of the 21st century” should begin long before the manifestation of obvious signs of the disease. This clinical case emphasizes the relevance of this problem in medical practice. Active identification and prevention of the initial manifestations of this disease in young people will help reduce the risk of developing comorbid diseases. Patients with NAFLD and obesity have an increased risk of various complications, therefore, they need more medical attention and frequent monitoring of liver indices and functional status.

Maternal sucralose exposure induces Paneth cell defects and exacerbates gut dysbiosis of progeny mice

2021 ◽  
Author(s):  
Xin Dai ◽  
Chen Wang ◽  
Zixuan Guo ◽  
Yun Li ◽  
Tianyu Liu ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Liver Disease ◽  
Gut Microbiota ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Paneth Cell ◽  
Alcoholic Fatty Liver ◽  
Gut Dysbiosis ◽  
Alcoholic Fatty Liver Disease

Research has shown that maternal sucralose (MS) exposure alters the gut microbiota of offspring at weaning and predisposes the offspring to developing obesity, non-alcoholic fatty liver disease and metabolic syndrome...

scholarly journals Probiotics and Prebiotics as a Strategy for Non-Alcoholic Fatty Liver Disease, a Narrative Review

Foods ◽  
2021 ◽  
Vol 10 (8) ◽  
pp. 1719
Author(s):  
Valentina Castillo ◽  
Fernanda Figueroa ◽  
Karoll González-Pizarro ◽  
Paz Jopia ◽  
Claudia Ibacache-Quiroga
Keyword(s):  
Liver Disease ◽  
Gut Microbiota ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Communicable Disease ◽  
Anthropometric Parameters ◽  
Alcoholic Fatty Liver ◽  
Risks Factors ◽  
Alcoholic Fatty Liver Disease ◽  
Non Communicable Disease

Non-alcoholic fatty liver disease (NAFLD) is a chronic non-communicable disease, with a prevalence of 25% worldwide. This pathology is a multifactorial illness, and is associated with different risks factors, including hypertension, hyperglycemia, dyslipidemia, and obesity. Beside these predisposing features, NAFLD has been related to changes in the microbiota, which favor the disease progression. In this context, the modulation of the gut microbiota has emerged as a new therapeutic target for the prophylaxis and treatment of NAFLD. This review describes the changes in the gut microbiota associated with NAFLD and the effect of probiotics, prebiotics, and synbiotics on the gut microbiota, liver damage, anthropometric parameters, blood lipids, inflammation markers and insulin resistance in these patients.

scholarly journals Mechanisms of Non-Alcoholic Fatty Liver Disease in the Metabolic Syndrome. A Narrative Review

Antioxidants ◽  
2021 ◽  
Vol 10 (2) ◽  
pp. 270
Author(s):  
Luca Rinaldi ◽  
Pia Clara Pafundi ◽  
Raffaele Galiero ◽  
Alfredo Caturano ◽  
Maria Vittoria Morone ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Risk Factor ◽  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Smoking Habit ◽  
Lifestyle Modifications ◽  
Alcoholic Fatty Liver ◽  
The Metabolic Syndrome ◽  
Alcoholic Fatty Liver Disease

Non-alcoholic fatty liver disease (NAFLD) and metabolic syndrome (MS) are two different entities sharing common clinical and physio-pathological features, with insulin resistance (IR) as the most relevant. Large evidence leads to consider it as a risk factor for cardiovascular disease, regardless of age, sex, smoking habit, cholesterolemia, and other elements of MS. Therapeutic strategies remain still unclear, but lifestyle modifications (diet, physical exercise, and weight loss) determine an improvement in IR, MS, and both clinical and histologic liver picture. NAFLD and IR are bidirectionally correlated and, consequently, the development of pre-diabetes and diabetes is the most direct consequence at the extrahepatic level. In turn, type 2 diabetes is a well-known risk factor for multiorgan damage, including an involvement of cardiovascular system, kidney and peripheral nervous system. The increased MS incidence worldwide, above all due to changes in diet and lifestyle, is associated with an equally significant increase in NAFLD, with a subsequent rise in both morbidity and mortality due to both metabolic, hepatic and cardiovascular diseases. Therefore, the slowdown in the increase of the “bad company” constituted by MS and NAFLD, with all the consequent direct and indirect costs, represents one of the main challenges for the National Health Systems.

scholarly journals FibroTest for Evaluating Fibrosis in Non-Alcoholic Fatty Liver Disease Patients: A Systematic Review and Meta-Analysis

2021 ◽  
Vol 10 (11) ◽  
pp. 2415
Author(s):  
Yasaman Vali ◽  
Jenny Lee ◽  
Jérôme Boursier ◽  
René Spijker ◽  
Joanne Verheij ◽  
...  
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Meta Analysis ◽  
Advanced Fibrosis ◽  
Alcoholic Fatty Liver ◽  
Multiple Thresholds ◽  
Meta Analyses ◽  
Alcoholic Fatty Liver Disease

(1) Background: FibroTest™ is a multi-marker panel, suggested by guidelines as one of the surrogate markers with acceptable performance for detecting fibrosis in patients with non-alcoholic fatty liver disease (NAFLD). A number of studies evaluating this test have been published after publication of the guidelines. This study aims to produce summary estimates of FibroTest™ diagnostic accuracy. (2) Methods: Five databases were searched for studies that evaluated FibroTest™ against liver biopsy as the reference standard in NAFLD patients. Two authors independently screened the references, extracted data, and assessed the quality of included studies. Meta-analyses of the accuracy in detecting different levels of fibrosis were performed using the bivariate random-effects model and the linear mixed-effects multiple thresholds model. (3) Results: From ten included studies, seven were eligible for inclusion in our meta-analysis. Five studies were included in the meta-analysis of FibroTest™ in detecting advanced fibrosis and five in significant fibrosis, resulting in an AUC of 0.77 for both target conditions. The meta-analysis of three studies resulted in an AUC of 0.69 in detecting any fibrosis, while analysis of three other studies showed higher accuracy in cirrhosis (AUC: 0.92). (4) Conclusions: Our meta-analysis showed acceptable performance (AUC > 0.80) of FibroTest™ only in detecting cirrhosis. We observed more limited performance of the test in detecting significant and advanced fibrosis in NAFLD patients. Further primary studies with high methodological quality are required to validate the reliability of the test for detecting different fibrosis levels and to compare the performance of the test in different settings.

Sign in / Sign up

Export Citation Format

Share Document